Business

Cipla Q3 net profit dips 57 per cent due to Lanreotide production halt

Lanreotide is used to treat growth hormone disorder and is among Cipla’s top three products in the US market

Economist AdminEconomist Admin
Cipla Q3 net profit dips 57 per cent due to Lanreotide production halt
Lanreotide is used to treat growth hormone disorder and is among Cipla’s top three products in the US market
Read More

Tags:

Previous Article

Axis Bank places consumer lending arm's stake sale on hold, sources say

Next Article

Airlines offered Bengaluru, Hyderabad and Lucknow slots after Indigo flight disr...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Economist Admin
Economist Admin Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.

Related Posts

Standard Chartered prefers organic growth over acquisitions in India, says CEO PD Singh

Standard Chartered prefers organic growth over acquisit...

FEDA-HQ

Deutsche Bank’s $2.5 billion India retail assets draw final bids

Deutsche Bank’s $2.5 billion India retail assets draw f...

Economist Admin

Banks head into Q3 earnings with strong loan growth—but deposits, liquidity in focus

Banks head into Q3 earnings with strong loan growth—but...

Economist Admin